Search form

MASAC Recommendations Regarding Radionuclide Synovectomy

PrintFriendly

Printer Friendly and PDF

MASAC Recommendation: 194

MASAC Recommendations Regarding Radionuclide Synovectomy

Date: 
June 26, 2010
Revisions: 
176
AttachmentSize
MASAC Document27.06 KB
  • Radionuclide synovectomy (RS) utilizing phosphorous 32-sulfur colloid (P32) has been performed in Canada since 1977 and in the United States since 1988 for rheumatoid arthritis. (1) In individuals with hemophilia and chronic synovitis, the procedure is used to reduce recurrent joint bleeding.  In contrast to surgical synovectomy options, RS is relatively inexpensive and requires little factor coverage. Extensive post-procedure rehabilitation is not required to maintain good joint range-of-motion.

    P32, the only isotope currently utilized for RS in North America, was chosen for its larger particle size, pure beta emission, and longer half-life.  A review of the efficacy and safety of this procedure published in 2002 found no reports of malignancy associated with P32 RS. (2)  Since this initial review, there have been two cases of acute lymphoblastic leukemia (ALL) reported in children with hemophilia after RS: one with precursor B-cell ALL and another with T-cell ALL.(3,4)  Both patients developed leukemia within one year after uncomplicated RS, much earlier than the expected peak of radiation-induced leukemia. (5, 6)  Also, both patients manifested a history of an unusual immunologic/inflammatory or autoimmune disorder prior to the development of leukemia.  The patient with precursor B-cell ALL has been in remission for 10 years; the patient with T-cell ALL had a relapse and died.

    There have been approximately 1100 RS procedures performed in 700 patients with hemophilia, both adults and children, in the United States since 1988. The overall cancer rate in persons with hemophilia is not known, but in one NIH-funded prospective study of malignancy in over 3,000 individuals with hemophilia in the U.S., the rate of leukemia was low, less than 1 in 33,000 person-years.(7)   Pediatric ALL has a yearly incidence of 1 in 2500 children under age 15.  Estimates from the CDC (number of hemophilia patients; HSS data) and the NCI (incidence of leukemia; SEER data) would suggest that there should have been 1.5 cases of ALL in the hemophilia population over the last 10 years.  These 2 cases are the only reported cases of malignancy among persons with hemophilia or rheumatoid arthritis who have received the isotope P32.  Due to the low frequency and the short interval between exposure and development of leukemia in these two cases, the casual relationship between radiation exposure and malignancy cannot be established conclusively, but possible causality cannot be ruled out. Additionally, the biology and epidemiology of pediatric acute lymphoblastic leukemia and adult ALL differ greatly. The majority of RS procedures have been performed in adults, so it is unclear whether these 2 pediatric ALL cases have significance for radionuclide synovectomies done in adults with hemophilia.

    Accordingly, MASAC recommends the following guidelines when considering this procedure in hemophilia patients with chronic synovitis:

    1. RS should be considered for patients with chronic synovitis or chronic joint bleeds not responsive to replacement therapy in whom a surgical synovectomy might pose excessive risk due to associated co-morbities and for patients who are a post-surgical rehabilitative risk due to non-compliance.

    2. Discussion about the risk/benefit ratio of RS, including the potential risk of cancer, should be undertaken with all individuals considering the procedure.

    3. Written informed consent should be obtained and should clearly document that these two cases of malignancy were discussed.

    4. A standard RS protocol published in the literature (2, 3) should be utilized.  It should include arthrogram documentation of intra-articular needle placement and P32 distribution. There should be concomitant steroid administration to decrease leakage and inflammation.

    5. All patients undergoing RS should be enrolled in a nationwide registry. Malignancy data in persons with hemophilia and a registry of all patients undergoing RS should be collected by ATHN.

     

    References:

    1. Rivard GE, Girad M, Belanger R, et al. Synoviorthesis with colloidal 32P chromic phosphate for the treatment of hemophilic arthropathy.  J Bone and Joint Surgery 1994; 76:482-8.

    2. Dunn AL, Busch MT, Wyly JB, Abshire TC. Radionuclide synovectomy for hemophilic arthropathy: A comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol.  Thromb Haemost 2002; 87:383-393.

    3. Manco-Johnson MJ, Nuss R, Lear J, Wiedel J, Geraghty SJ, Hacker MR, et al.  P32 Radiosynoviorthesis in children with hemophilia. J Ped Hematol/Onc 2002; 24:534-9.

    4. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC.  Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005; 3:1541.

    5. Wakeford R. The cancer epidemiology of radiation.  Oncogene 2004; 23:6404-28.

    6. Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr. Radiol. 2006; 36 (Suppl 2): 121-5.

    7. Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC, McMillan CW, Lovrien EW, Aledort LM, et al. Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma and other malignancies in patients with hemophilia.  Blood 1993; 81:1889-97.

     

    This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.

     

    Copyright 2010 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at www.hemophilia.org.